Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia

Med Clin (Barc). 2020 Dec 24;155(12):548-556. doi: 10.1016/j.medcli.2020.07.002. Epub 2020 Jul 10.

[Article in English, Spanish]

Authors

Zulvikar Syambani Ulhaq¹, Gita Vita Soraya²

Affiliations

¹ Department of Biochemistry, Faculty of Medicine and Health Sciences, Maulana Malik Ibrahim Islamic State University of Malang, Batu, East Java 65151, Indonesia. Electronic address: zulhaq@kedokteran.uin-malang.ac.id.
² Department of Biochemistry, Faculty of Medicine, Hasanuddin University, Makassar, South Sulawesi 90245, Indonesia.

No abstract available

Publication types

Meta-Analysis
Systematic Review

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Antiviral Agents / therapeutic use
C-Reactive Protein / analysis
COVID-19 / therapy*
COVID-19 Drug Treatment*
Case-Control Studies
Clinical Trials as Topic
Combined Modality Therapy
Female
Humans
Interleukin-6 / genetics*
Interleukin-6 / physiology
Male
Middle Aged
Polymorphism, Genetic
Polymorphism, Single Nucleotide*
Promoter Regions, Genetic / genetics*
Receptors, Interleukin-6 / antagonists & inhibitors*
Respiration, Artificial
SARS-CoV-2*

Substances

Antibodies, Monoclonal, Humanized
Antiviral Agents
IL6 protein, human
Interleukin-6
Receptors, Interleukin-6
C-Reactive Protein
tocilizumab